Novo Nordisk Strikes $2.1B Deal with Omeros to License Rare Disease Drug
Danes’ biotech powerhouse Novo Nordisk has agreed to pay up to $2.1 billion to license and acquire rights to Omeros’ experimental drug, zaltenibart, positioning itself for a bigger role in rare disease treatment. Under the deal, Novo will gain global development and marketing rights to zaltenibart, while Omeros receives $340 million upfront, plus additional milestone…